Medtronic plc (MDT) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$93.75

Open

$93.44

Day range

$92.42 – $94.54

Volume

9.9M

About Medtronic plc

Latest MDT news

• Titanium and refractory metal powders producer Amaero sets terms for $53 million Nasdaq crosslisting
  IPO & M&A · Sep 15, 2026

  Amaero International, a producer of titanium and refractory metal powders, has announced the terms for its cross-listing on the Nasdaq, aiming to raise approximately $53 million. The company plans to issue 7.5 million American Depositary Shares (ADS) at a price range of $6.50 to $7.50 per share. This strategic move is expected to enhance Amaero's visibility and access to capital markets, potentially fueling its growth in the burgeoning additive manufacturing sector. The cross-listing comes at a time when demand for advanced materials, particularly titanium, is on the rise, driven by applications in aerospace, automotive, and medical industries. Investors are closely watching the offering, as it could signal a broader trend of international companies seeking to tap into the U.S. market for increased liquidity and investor interest. Market analysts suggest that successful execution of this listing could bolster confidence in the materials sector, particularly for companies focused on innovative manufacturing processes.

• Jim Cramer Calls Medtronic (MDT) a “Quandary” as Growth Surges and Diabetes Exit Nears
  Yahoo Finance · Sep 10, 2026

  Jim Cramer has labeled Medtronic plc (NYSE: MDT) a “quandary” amid its impressive growth trajectory and impending exit from the diabetes market. During a recent episode of Mad Money, Cramer highlighted the paradox of Medtronic's strong performance in the healthcare sector, which is currently experiencing a bull market, while also grappling with significant strategic shifts. The company's decision to divest its diabetes business, which has been a cornerstone of its portfolio, raises questions about its future growth potential and overall market positioning. Medtronic's recent financial results indicate robust growth, driven by advancements in its core medical device segments. However, the impending exit from diabetes, a move aimed at refocusing resources and capital, could create volatility in investor sentiment. Analysts will be closely monitoring how this transition impacts Medtronic's revenue streams and market share in other areas, particularly as competition intensifies in the medical technology space. The company's ability to navigate this strategic pivot while maintaining investor confidence will be crucial in determining its stock performance in the coming months.

• Wall Street Isn't Talking About High-Yield Medtronic Stock -- Here's Why It Should Be
  Corporate Bonds · Sep 9, 2026

  Medtronic, a leading medical technology company, is garnering attention for its high-yield stock, which offers a compelling opportunity for income-focused investors. Despite the current market's preference for high-growth stocks, Medtronic's stable dividend and solid fundamentals position it as an attractive option for those looking to diversify their portfolios with lower-risk investments. The company's consistent performance in the healthcare sector, coupled with its status as a Dividend Aristocrat, underscores its reliability in generating income. The lack of buzz surrounding Medtronic's stock may be attributed to the prevailing trend favoring high-growth equities, which often overshadow more conservative investments. However, this presents a potential buying opportunity for savvy investors. With interest rates remaining relatively low, the appeal of Medtronic's dividend yield becomes even more pronounced, especially as market volatility continues to challenge growth-oriented stocks. As investors seek to balance their portfolios amidst economic uncertainty, Medtronic's high-yield offering could serve as a stabilizing force, making it a stock worth considering in the current climate.

• In the News: Muer Yang on Private Equity’s Medical Device Push
  Private Equity · Sep 8, 2026

  Muer Yang, a prominent figure in the private equity sector, has recently highlighted the growing interest of private equity firms in the medical device industry. This trend is largely driven by the sector's potential for high returns, bolstered by an aging population and increasing demand for innovative healthcare solutions. Yang noted that private equity investments in medical devices have surged, as firms seek to capitalize on advancements in technology and the ongoing shift towards minimally invasive procedures. The implications for the market are significant. As private equity firms inject capital into medical device companies, there is potential for accelerated innovation and development of new products. This influx of funding can enhance competition within the industry, leading to improved patient outcomes and potentially lowering costs in the long term. However, it also raises concerns about the sustainability of such investments, particularly if firms prioritize short-term gains over long-term viability. Yang emphasized the importance of strategic partnerships between private equity firms and medical device manufacturers to navigate regulatory challenges and market dynamics effectively. As this trend continues, stakeholders across the healthcare spectrum will need to monitor the evolving landscape, as the intersection of private equity and medical devices could reshape the future of healthcare delivery.

• Medtronic (MDT) Q1 2027 Earnings Call Transcript
  Yahoo Finance · Sep 8, 2026

  Medtronic plc (NYSE: MDT) reported a strong performance in its first quarter of fiscal 2027, with revenues reaching $9.8 billion, reflecting a 13.7% increase year-over-year on both a reported and organic basis. Although the company posted a non-GAAP diluted earnings per share (EPS) of $1.55, slightly below the consensus estimate of $1.56, the overall results were positively received by the market. In premarket trading, Medtronic's stock surged by 9%, driven by the earnings beat and an optimistic outlook for the fiscal year. Management highlighted that growth is broadening across major franchises, with newer platforms gaining traction and scale. Additionally, Medtronic announced a significant $700 million distribution deal focused on robotic surgery, which is expected to enhance its competitive position in the rapidly evolving surgical technology market. The company also raised its full-year guidance, signaling confidence in sustained growth and operational improvements. This combination of factors positions Medtronic favorably as it navigates the complexities of the healthcare landscape, potentially attracting further investor interest in the coming quarters.

• M&A Update: Is DME Still Attractive to Investors?
  IPO & M&A · Sep 4, 2026

  The durable medical equipment (DME) sector continues to draw attention from investors, despite recent fluctuations in the broader healthcare market. With an aging population and increasing demand for home healthcare solutions, DME companies are positioned to benefit from long-term growth trends. Recent mergers and acquisitions in the sector highlight ongoing interest, as firms seek to consolidate resources and expand their market reach. However, potential investors must navigate challenges such as regulatory scrutiny and reimbursement pressures that could impact profitability. The recent uptick in interest rates may also affect financing conditions for M&A deals, potentially slowing down transaction volumes. Analysts suggest that while the DME market remains attractive, investors should conduct thorough due diligence to assess individual company fundamentals and market positioning before committing capital. As the landscape evolves, strategic partnerships and innovative product offerings will likely play a crucial role in determining which companies emerge as leaders in the DME space.

• 4 hard lessons that reshaped KKR’s Asia strategy
  Private Equity · Sep 4, 2026

  KKR has undergone a significant transformation in its Asia strategy, driven by four key lessons learned from its experiences in the region. The private equity giant has recognized the importance of adapting to local market dynamics, particularly in understanding cultural nuances and regulatory environments. This shift comes as KKR aims to enhance its investment approach in Asia, where rapid economic changes and varying market conditions require a more nuanced strategy. One of the critical lessons has been the necessity of building strong local partnerships. KKR has found that collaborating with regional firms not only provides valuable insights but also fosters trust and credibility in markets that can be challenging for foreign investors. This approach has led to more successful deal executions and better alignment with local business practices. Additionally, KKR has emphasized the importance of sector-specific expertise, focusing on industries that are poised for growth in Asia, such as technology and healthcare. Market implications of KKR's refined strategy could be significant, as the firm positions itself to capitalize on emerging opportunities in the region. With Asia's economic landscape continuing to evolve, KKR's lessons learned may serve as a blueprint for other investors looking to navigate the complexities of the market. As competition intensifies among private equity firms in Asia, those that can effectively adapt their strategies to local conditions will likely gain a competitive edge, potentially reshaping investment flows in the region.

• These stocks in the red-hot healthcare sector have gotten too crowded to own
  MarketWatch · Sep 4, 2026

  The healthcare sector has seen a surge in investor interest, but analysts are now cautioning that certain stocks may be overextended. Notably, GE HealthCare and Medtronic have attracted a significant number of bullish bets, leading to concerns that these stocks have become too crowded to hold. This crowded trade could indicate a potential reversal, as excessive optimism often precedes corrections in the market. Market experts are recommending options strategies that bet against these stocks, suggesting that the prevailing sentiment may not be sustainable. With valuations stretched and a growing number of investors positioned for further gains, any negative news or earnings misses could trigger a swift sell-off. As the healthcare sector continues to evolve, investors may need to reassess their positions to avoid being caught in a downturn. The implications of this crowded trade extend beyond individual stocks, potentially influencing broader market sentiment in the healthcare space.

• Wearable Bioelectronic Skin Patches Market Outlook Highlights Strategic Opportunities Across The Industry
  Market Outlook · Sep 2, 2026

  The global wearable bioelectronic skin patches market is on a significant growth trajectory, projected to reach approximately USD 6.15 billion by 2030, with a compound annual growth rate (CAGR) of 22.3% from 2024. This surge is driven by increasing clinical adoption of advanced monitoring solutions, particularly single-lead ambulatory ECG patch monitors, which are becoming essential in the detection and management of conditions such as atrial fibrillation. The demand for non-invasive, real-time health monitoring technologies is further propelling market expansion, as healthcare providers seek efficient ways to enhance patient care. Strategic opportunities within the industry are emerging as companies invest in innovative technologies, including advanced sensors and biocompatible materials. However, the high costs associated with research, development, and manufacturing pose challenges for market players. As competition intensifies, firms will need to balance quality and affordability to capture market share effectively. The anticipated growth in this sector not only reflects a shift towards personalized healthcare solutions but also highlights the potential for wearable technology to transform patient monitoring and management practices across various healthcare settings.

• Medtronic's Diabetes Spinoff Just Surged. What To Look For In Its Earnings.
  Yahoo Finance · Sep 1, 2026

  Medtronic's recent spinoff, Minimed, has seen a significant surge in its stock price following the announcement of improved full-year guidance for both companies. This uptick comes on the heels of Medtronic reporting organic sales growth, which has bolstered investor confidence in the future performance of its diabetes division. The positive momentum in Minimed's stock reflects a broader optimism about the company's potential to capture market share in the growing diabetes management sector. As investors look ahead to Minimed's upcoming earnings report, key metrics to watch will include revenue growth, market penetration, and advancements in product offerings, particularly in continuous glucose monitoring and insulin delivery systems. Analysts will also be keen to assess how effectively Minimed is navigating the competitive landscape, especially with increasing pressure from other players in the diabetes technology market. A strong earnings performance could further solidify Minimed's position and enhance Medtronic's overall valuation, while any disappointing results may lead to volatility in both stocks.

All 29 articles in the app →

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen